Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...

Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent's neladalkib and zidesamtinib from an undisclosed ...

Royalty Pharma is acquiring a low-single digit pre-existing royalty on worldwide net sales on each of Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. The ...

Founded in 1964, Alger is recognized as a pioneer of growth-style investment management. Privately-owned and headquartered in New York City, Alger can help "Unlock Your Growth Potential" through a ...

If the trends of the first three quarters continue in the fourth, the amount of money raised by Bay State startups could be ...

Microsoft shares underperformed due to concerns about its relationship with OpenAI following the Oracle/OpenAI deal ...

The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

These companies could innovate their way to success.

CFOs, including Gunnar Wiedenfels of Warner Bros Discovery and Colette Kress of Nvidia, addressed disciplined spending, ...

The International Society for Stem Cell Research (ISSCR) today opened its sold-out international symposium, Accelerating ...